Pelthos Therapeutics Inc. (PTHS) 10-Year Financial Performance & Capital Metrics

PTHS • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections

AboutPelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.Show more

Revenue $0
EBITDA -$7M -4.5%
Net Income -$8M -7.8%
EPS (Diluted) -13.54 -5.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -9.63 +27.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-134.23%

EPS CAGR

10Y-

5Y-

3Y-

TTM-102.62%

ROCE

10Y Avg-

5Y Avg-

3Y Avg-

Latest-

Peer Comparison

Antibiotics & Bacterial Infections

Name	Market Cap	Current Price	P/E Ratio	Net Margin	ROE	Debt/Equity
PLRZPolyrizon Ltd.	16.19M	15.54	31.08		-5.21%
TOVXTheriva Biologics, Inc.	7.49M	0.21	-0.01		-388.69%	0.08
CTXRCitius Pharmaceuticals, Inc.	17.79M	0.86	-0.14	-258.23%	-59.6%	0.00
ACXPAcurx Pharmaceuticals, Inc.	6.32M	2.69	-0.15		-0.25%
ITRMIterum Therapeutics plc	17.16M	0.32	-0.26	-69.13%
ANTXAN2 Therapeutics, Inc.	34.25M	1.25	-0.73		-56.29%
MCRBSeres Therapeutics, Inc.	137.33M	15.18	-0.80	15.37%	12.34%	6.65
PYPDPolyPid Ltd.	73.03M	4.39	-0.89		-10.39%	1.25

Profit & Loss

	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0
Revenue Growth %	-	-	-
Cost of Goods Sold+	0	0	0
COGS % of Revenue	-	-	-
Gross Profit+	0	0	0
Gross Margin %	-	-	-
Gross Profit Growth %	-	-	-
Operating Expenses+	2.32M	6.86M	7.57M
OpEx % of Revenue	-	-	-
Selling, General & Admin	1.93M	4.28M	6.39M
SG&A % of Revenue	-	-	-
Research & Development	391.73K	2.58M	1.18M
R&D % of Revenue	-	-	-
Other Operating Expenses	0	0	0
Operating Income+	-2.32M	-6.86M	-7.57M
Operating Margin %	-	-	-
Operating Income Growth %	-	-1.96%	-0.1%
EBITDA+	-2.32M	-6.86M	-7.17M
EBITDA Margin %	-	-	-
EBITDA Growth %	-	-1.96%	-0.04%
D&A (Non-Cash Add-back)	0	0	0
EBIT	-2.32M	-6.86M	-7.17M
Net Interest Income+	-140.43K	-518.51K	-786.39K
Interest Income	0	0	0
Interest Expense	140.43K	518.51K	786.39K
Other Income/Expense	-140.43K	-518.51K	-383.89K
Pretax Income+	-2.46M	-7.38M	-7.96M
Pretax Margin %	-	-	-
Income Tax+	0	0	0
Effective Tax Rate %	1%	1%	1%
Net Income+	-2.46M	-7.38M	-7.96M
Net Margin %	-	-	-
Net Income Growth %	-	-2%	-0.08%
Net Income (Continuing)	-2.46M	-7.38M	-7.96M
Discontinued Operations	0	0	0
Minority Interest	0	0	0
EPS (Diluted)+	-4.26	-12.80	-13.54
EPS Growth %	-	-2%	-0.06%
EPS (Basic)	-4.26	-12.80	-13.54
Diluted Shares Outstanding	576.75K	576.75K	587.62K
Basic Shares Outstanding	576.75K	576.75K	587.62K
Dividend Payout Ratio	-	-	-

Balance Sheet

	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	55.07K	96.39K	1.37M
Cash & Short-Term Investments	55.07K	96.39K	513.44K
Cash Only	55.07K	96.39K	513.44K
Short-Term Investments	0	0	0
Accounts Receivable	0	0	40.4K
Days Sales Outstanding	-	-	-
Inventory	0	0	0
Days Inventory Outstanding	-	-	-
Other Current Assets	0	0	750K
Total Non-Current Assets+	0	0	0
Property, Plant & Equipment	0	0	0
Fixed Asset Turnover	-	-	-
Goodwill	0	0	0
Intangible Assets	0	0	0
Long-Term Investments	0	0	0
Other Non-Current Assets	0	0	0
Total Assets+	55.07K	96.39K	1.37M
Asset Turnover	-	-	-
Asset Growth %	-	0.75%	13.2%
Total Current Liabilities+	3.76M	6.54M	4.08M
Accounts Payable	2.99M	4.62M	1.9M
Days Payables Outstanding	-	-	-
Short-Term Debt	540.43K	1.27M	2.19M
Deferred Revenue (Current)	0	0	0
Other Current Liabilities	221.88K	645.95K	0
Current Ratio	0.01x	0.01x	0.34x
Quick Ratio	0.01x	0.01x	0.34x
Cash Conversion Cycle	-	-	-
Total Non-Current Liabilities+	0	0	0
Long-Term Debt	0	0	0
Capital Lease Obligations	0	0	0
Deferred Tax Liabilities	0	0	0
Other Non-Current Liabilities	0	0	0
Total Liabilities	3.76M	6.54M	4.08M
Total Debt+	540.43K	1.27M	2.19M
Net Debt	485.36K	1.17M	1.67M
Debt / Equity	-	-	-
Debt / EBITDA	-	-	-
Net Debt / EBITDA	-	-	-
Interest Coverage	-16.51x	-13.23x	-9.63x
Total Equity+	-3.71M	-6.44M	-2.71M
Equity Growth %	-	-0.74%	0.58%
Book Value per Share	-6.43	-11.17	-4.62
Total Shareholders' Equity	-3.71M	-6.44M	-2.71M
Common Stock	111	391	613
Retained Earnings	-6.14M	-13.52M	-21.47M
Treasury Stock	0	0	0
Accumulated OCI	0	0	0
Minority Interest	0	0	0

Cash Flow

	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.57M	-981.03K	-5.79M
Operating CF Margin %	-	-	-
Operating CF Growth %	-	0.37%	-4.9%
Net Income	-2.46M	-7.38M	-7.96M
Depreciation & Amortization	0	0	0
Stock-Based Compensation	110.15K	1.73M	1.8M
Deferred Taxes	0	0	0
Other Non-Cash Items	140.43K	2.62M	328.93K
Working Capital Changes	640.86K	2.05M	34.63K
Change in Receivables	0	0	-45.79K
Change in Inventory	0	0	0
Change in Payables	413.6K	1.63M	1.18M
Cash from Investing+	0	0	0
Capital Expenditures	0	0	0
CapEx % of Revenue	-	-	-
Acquisitions	-	-	-
Investments	-	-	-
Other Investing	0	0	0
Cash from Financing+	1.62M	1.02M	6.21M
Debt Issued (Net)	-	-	-
Equity Issued (Net)	-	-	-
Dividends Paid	0	0	0
Share Repurchases	-	-	-
Other Financing	1.22M	0	0
Net Change in Cash	-	-	-
Free Cash Flow+	-1.57M	-981.03K	-5.79M
FCF Margin %	-	-	-
FCF Growth %	-	0.37%	-4.9%
FCF per Share	-2.72	-1.70	-9.86
FCF Conversion (FCF/Net Income)	0.64x	0.13x	0.73x
Interest Paid	0	0	0
Taxes Paid	0	0	0

Key Ratios

Metric	2022	2023	2024
Interest Coverage	-16.51x	-13.23x	-9.63x
FCF Conversion	0.64x	0.13x	0.73x

Frequently Asked Questions

Growth & Financials

Pelthos Therapeutics Inc. (PTHS) reported $7.4M in revenue for fiscal year 2024.

Pelthos Therapeutics Inc. (PTHS) grew revenue by 0.0% over the past year. Growth has been modest.

Pelthos Therapeutics Inc. (PTHS) reported a net loss of $23.6M for fiscal year 2024.

Dividend & Returns

Pelthos Therapeutics Inc. (PTHS) had negative free cash flow of $17.0M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener